Findings from the MEDALIST trial revealed a significant reduction in transfusion burden for patients being treated with luspatercept compared with placebo
Although CAR-T alone has shown utility in CLL, evidence suggests the addition of ibrutinib could improve the durability of remission.
Favorable data on liso-cel bolsters its chances of moving into further stages of development, provided complete responses remain durable.
High rates of PFS found with salvage treatment with BRB regimen in patients with R/R Waldenström macroglobulinemia.
Stringent CR criteria may not predict clinical outcomes for patients with MM.
US FDA recently approved rituximab biosimilar as monotherapy and in combination with chemotherapy.
The need for dose reductions did not significantly affect progression-free survival in patients with WM treated with ibrutinib.
Although the study suggested the efficacy of the branded version was superior to its generic counterpart, more research may be necessary to tease out manufacturer differences.
Results of a comparison study, presented at ASH 2018, found that salvage HDCT followed by ASCT in patients with relapsed MM did not lead to significant difference in PFS or OS compared with continuous novel agent-based treatment.
Study shows risk of second primary malignancy or transformation to lymphoma is low.
Please login or register first to view this content.
